APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nivolumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nivolumab Market Outlook and Growth Opportunities 2026

23 December 2025191 pages

Choose your research edition.

Industry ResearchNivolumab Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Nivolumab Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Nivolumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nivolumab Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Nivolumab Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Nivolumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nivolumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nivolumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nivolumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nivolumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nivolumab market include Ono Pharmaceutical and Bristol-Myers Squibb among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nivolumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nivolumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nivolumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nivolumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Nivolumab Segment by Company

Ono Pharmaceutical

Bristol-Myers Squibb

Nivolumab Segment by Type

Injection 4mL

Injection 10mL

Nivolumab Segment by Application

Metastatic Squamous NSCLC

Metastatic Melanoma

Renal Cell Carcinoma

Classical Hodgkin Lymphoma

Unresectable Melanoma

Others

Nivolumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nivolumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nivolumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nivolumab significant trends, drivers, influence factors in global and regions.

6. To analyze Nivolumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nivolumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nivolumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nivolumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nivolumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nivolumab industry.

Chapter 3: Detailed analysis of Nivolumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nivolumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nivolumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nivolumab Industry Trends Table 2. Nivolumab Industry Drivers Table 3. Nivolumab Industry Opportunities and Challenges Table 4. Nivolumab Industry Restraints Table 5. Global Nivolumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nivolumab Revenue Share by Company (2021-2026) Table 7. Global Nivolumab Sales Volume by Company (k units) & (2021-2026) Table 8. Global Nivolumab Sales Volume Share by Company (2021-2026) Table 9. Global Nivolumab Average Price (US$/unit) of Company (2021-2026) Table 10. Global Nivolumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nivolumab Key Company Manufacturing Base & Headquarters Table 12. Global Nivolumab Company, Product Type & Application Table 13. Global Nivolumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nivolumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injection 4mL Table 18. Significant Companies of Injection 10mL Table 19. Global Nivolumab Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Nivolumab Sales Volume by Type (2021-2026) & (k units) Table 21. Global Nivolumab Sales Volume by Type (2027-2032) & (k units) Table 22. Global Nivolumab Sales Volume Share by Type (2021-2026) Table 23. Global Nivolumab Sales Volume Share by Type (2027-2032) Table 24. Global Nivolumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Nivolumab Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Nivolumab Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Nivolumab Sales Value Share by Type (2021-2026) Table 28. Global Nivolumab Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Metastatic Squamous NSCLC Table 30. Significant Companies of Metastatic Melanoma Table 31. Significant Companies of Renal Cell Carcinoma Table 32. Significant Companies of Classical Hodgkin Lymphoma Table 33. Significant Companies of Unresectable Melanoma Table 34. Significant Companies of Others Table 35. Global Nivolumab Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Nivolumab Sales Volume by Application (2021-2026) & (k units) Table 37. Global Nivolumab Sales Volume by Application (2027-2032) & (k units) Table 38. Global Nivolumab Sales Volume Share by Application (2021-2026) Table 39. Global Nivolumab Sales Volume Share by Application (2027-2032) Table 40. Global Nivolumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Nivolumab Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Nivolumab Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Nivolumab Sales Value Share by Application (2021-2026) Table 44. Global Nivolumab Sales Value Share by Application (2027-2032) Table 45. Global Nivolumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Nivolumab Sales by Region (2021-2026) & (k units) Table 47. Global Nivolumab Sales Market Share by Region (2021-2026) Table 48. Global Nivolumab Sales by Region (2027-2032) & (k units) Table 49. Global Nivolumab Sales Market Share by Region (2027-2032) Table 50. Global Nivolumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Nivolumab Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Nivolumab Sales Value Share by Region (2021-2026) Table 53. Global Nivolumab Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Nivolumab Sales Value Share by Region (2027-2032) Table 55. Global Nivolumab Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Nivolumab Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Nivolumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Nivolumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Nivolumab Sales by Country (2021-2026) & (k units) Table 60. Global Nivolumab Sales Market Share by Country (2021-2026) Table 61. Global Nivolumab Sales by Country (2027-2032) & (k units) Table 62. Global Nivolumab Sales Market Share by Country (2027-2032) Table 63. Global Nivolumab Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Nivolumab Sales Value Market Share by Country (2021-2026) Table 65. Global Nivolumab Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Nivolumab Sales Value Market Share by Country (2027-2032) Table 67. Ono Pharmaceutical Company Information Table 68. Ono Pharmaceutical Business Overview Table 69. Ono Pharmaceutical Nivolumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Ono Pharmaceutical Nivolumab Product Portfolio Table 71. Ono Pharmaceutical Recent Development Table 72. Bristol-Myers Squibb Company Information Table 73. Bristol-Myers Squibb Business Overview Table 74. Bristol-Myers Squibb Nivolumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Bristol-Myers Squibb Nivolumab Product Portfolio Table 76. Bristol-Myers Squibb Recent Development Table 77. Key Raw Materials Table 78. Raw Materials Key Suppliers Table 79. Nivolumab Distributors List Table 80. Nivolumab Customers List Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Nivolumab Product Image Figure 2. Global Nivolumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nivolumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nivolumab Sales (2021-2032) & (k units) Figure 5. Global Nivolumab Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Nivolumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injection 4mL Image Figure 10. Injection 10mL Image Figure 11. Global Nivolumab Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Nivolumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Nivolumab Sales Volume Share by Type (2021-2032) Figure 14. Global Nivolumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Nivolumab Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Nivolumab Sales Value Share by Type (2021-2032) Figure 17. Metastatic Squamous NSCLC Image Figure 18. Metastatic Melanoma Image Figure 19. Renal Cell Carcinoma Image Figure 20. Classical Hodgkin Lymphoma Image Figure 21. Unresectable Melanoma Image Figure 22. Others Image Figure 23. Global Nivolumab Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Nivolumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Nivolumab Sales Volume Share by Application (2021-2032) Figure 26. Global Nivolumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Nivolumab Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Nivolumab Sales Value Share by Application (2021-2032) Figure 29. Global Nivolumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Nivolumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Nivolumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Nivolumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Nivolumab Sales Value (2021-2032) & (US$ Million) Figure 34. North America Nivolumab Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Nivolumab Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Nivolumab Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Nivolumab Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Nivolumab Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Nivolumab Sales Value (2021-2032) & (US$ Million) Figure 40. South America Nivolumab Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Nivolumab Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Nivolumab Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Nivolumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Nivolumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Nivolumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Nivolumab Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Nivolumab Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Injection 4mL
  • Injection 10mL
Applications
  • Metastatic Squamous NSCLC
  • Metastatic Melanoma
  • Renal Cell Carcinoma
  • Classical Hodgkin Lymphoma
  • Unresectable Melanoma
  • Others
Companies covered
  • Ono Pharmaceutical
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nivolumab Sales Value (2021-2032)
  4. 1.2.2 Global Nivolumab Sales Volume (2021-2032)
  5. 1.2.3 Global Nivolumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nivolumab Market Dynamics
  1. 2.1 Nivolumab Industry Trends
  2. 2.2 Nivolumab Industry Drivers
  3. 2.3 Nivolumab Industry Opportunities and Challenges
  4. 2.4 Nivolumab Industry Restraints
3 Nivolumab Market by Company
  1. 3.1 Global Nivolumab Company Revenue Ranking in 2025
  2. 3.2 Global Nivolumab Revenue by Company (2021-2026)
  3. 3.3 Global Nivolumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Nivolumab Average Price by Company (2021-2026)
  5. 3.5 Global Nivolumab Company Ranking (2024-2026)
  6. 3.6 Global Nivolumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Nivolumab Company Product Type and Application
  8. 3.8 Global Nivolumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nivolumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nivolumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nivolumab Market by Type
  1. 4.1 Nivolumab Type Introduction
  2. 4.1.1 Injection 4mL
  3. 4.1.2 Injection 10mL
  4. 4.2 Global Nivolumab Sales Volume by Type
  5. 4.2.1 Global Nivolumab Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Nivolumab Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Nivolumab Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Nivolumab Sales Value by Type
  9. 4.3.1 Global Nivolumab Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Nivolumab Sales Value by Type (2021-2032)
  11. 4.3.3 Global Nivolumab Sales Value Share by Type (2021-2032)
5 Nivolumab Market by Application
  1. 5.1 Nivolumab Application Introduction
  2. 5.1.1 Metastatic Squamous NSCLC
  3. 5.1.2 Metastatic Melanoma
  4. 5.1.3 Renal Cell Carcinoma
  5. 5.1.4 Classical Hodgkin Lymphoma
  6. 5.1.5 Unresectable Melanoma
  7. 5.1.6 Others
  8. 5.2 Global Nivolumab Sales Volume by Application
  9. 5.2.1 Global Nivolumab Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Nivolumab Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Nivolumab Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Nivolumab Sales Value by Application
  13. 5.3.1 Global Nivolumab Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Nivolumab Sales Value by Application (2021-2032)
  15. 5.3.3 Global Nivolumab Sales Value Share by Application (2021-2032)
6 Nivolumab Regional Sales and Value Analysis
  1. 6.1 Global Nivolumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nivolumab Sales by Region (2021-2032)
  3. 6.2.1 Global Nivolumab Sales by Region: 2021-2026
  4. 6.2.2 Global Nivolumab Sales by Region (2027-2032)
  5. 6.3 Global Nivolumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nivolumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nivolumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nivolumab Sales Value by Region (2027-2032)
  9. 6.5 Global Nivolumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nivolumab Sales Value (2021-2032)
  12. 6.6.2 North America Nivolumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nivolumab Sales Value (2021-2032)
  15. 6.7.2 Europe Nivolumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nivolumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nivolumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nivolumab Sales Value (2021-2032)
  21. 6.9.2 South America Nivolumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nivolumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nivolumab Sales Value Share by Country, 2025 VS 2032
7 Nivolumab Country-level Sales and Value Analysis
  1. 7.1 Global Nivolumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nivolumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nivolumab Sales by Country (2021-2032)
  4. 7.3.1 Global Nivolumab Sales by Country (2021-2026)
  5. 7.3.2 Global Nivolumab Sales by Country (2027-2032)
  6. 7.4 Global Nivolumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nivolumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nivolumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nivolumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nivolumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nivolumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nivolumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nivolumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nivolumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nivolumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nivolumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nivolumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nivolumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nivolumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nivolumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nivolumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nivolumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nivolumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nivolumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nivolumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nivolumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nivolumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nivolumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nivolumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nivolumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nivolumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nivolumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nivolumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nivolumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nivolumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nivolumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nivolumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nivolumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nivolumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nivolumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nivolumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nivolumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nivolumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nivolumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nivolumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nivolumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nivolumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nivolumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nivolumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nivolumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nivolumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nivolumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nivolumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nivolumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nivolumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nivolumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nivolumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nivolumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nivolumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nivolumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nivolumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nivolumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nivolumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nivolumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nivolumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nivolumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nivolumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nivolumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nivolumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nivolumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nivolumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nivolumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nivolumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nivolumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nivolumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nivolumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nivolumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nivolumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nivolumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nivolumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nivolumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nivolumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nivolumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nivolumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nivolumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nivolumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nivolumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nivolumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nivolumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nivolumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nivolumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nivolumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Ono Pharmaceutical
  2. 8.1.1 Ono Pharmaceutical Company Information
  3. 8.1.2 Ono Pharmaceutical Business Overview
  4. 8.1.3 Ono Pharmaceutical Nivolumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Ono Pharmaceutical Nivolumab Product Portfolio
  6. 8.1.5 Ono Pharmaceutical Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Nivolumab Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Nivolumab Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nivolumab Value Chain Analysis
  2. 9.1.1 Nivolumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nivolumab Sales Mode & Process
  6. 9.2 Nivolumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nivolumab Distributors
  9. 9.2.3 Nivolumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst